Paper37035239
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.
Zhou FH and 5 others. Front Cell Dev Biol, 2023. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Papers, record 37035239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37035239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36153348 | Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. | NPJ Precis Oncol | 2022 | https://conductscience.org/library/papers/36153348 | PubMed |
| 2 | 29101163 | CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29101163 | PubMed |
| 3 | 34324367 | Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34324367 | PubMed |
| 4 | 29731395 | CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29731395 | PubMed |
| 5 | 29236940 | Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29236940 | PubMed |
| 6 | 34737452 | Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. | Nat Med | 2021 | https://conductscience.org/library/papers/34737452 | PubMed |
| 7 | 34544752 | INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34544752 | PubMed |
| 8 | 31563959 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/31563959 | PubMed |
| 9 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 10 | 30537512 | Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30537512 | PubMed |
| 11 | 35058503 | RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. | Sci Rep | 2022 | https://conductscience.org/library/papers/35058503 | PubMed |
| 12 | 35789445 | Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. | Breast Cancer Res Treat | 2022 | https://conductscience.org/library/papers/35789445 | PubMed |
| 13 | 27748766 | Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. | Oncogene | 2017 | https://conductscience.org/library/papers/27748766 | PubMed |
| 14 | 33460574 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33460574 | PubMed |
| 15 | 21367843 | Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. | Endocr Relat Cancer | 2011 | https://conductscience.org/library/papers/21367843 | PubMed |
| 16 | 31527167 | Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31527167 | PubMed |
| 17 | 29716919 | Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29716919 | PubMed |
| 18 | 30833638 | Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. | Oncogene | 2019 | https://conductscience.org/library/papers/30833638 | PubMed |
| 19 | 36071033 | High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. | Nat Commun | 2022 | https://conductscience.org/library/papers/36071033 | PubMed |
| 20 | 35263519 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35263519 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964697 | Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42964697 | PubMed |
| 42738414 | On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738414 | PubMed |
| 42658196 | Systematic analysis of network-driven adaptive resistance to CDK4/6 and oestrogen receptor inhibition using meta-dynamic network modelling. | Elife | 2026 | https://conductscience.org/library/papers/42658196 | PubMed |
| 42289616 | Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence. | Oncol Ther | 2026 | https://conductscience.org/library/papers/42289616 | PubMed |
| 42121857 | Pre-Adaptive States and Evolutionary Trajectories in Breast Cancer Drug Resistance: From Drug-Tolerant Persisters to Clonal Evolution. | Cells | 2026 | https://conductscience.org/library/papers/42121857 | PubMed |
| 42088350 | Dormancy exit correlates with CREB1 reactivation that is a potential target to overcome endocrine therapy resistance in ER+ breast cancer cells. | iScience | 2026 | https://conductscience.org/library/papers/42088350 | PubMed |
| 41893011 | Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors. | J Pers Med | 2026 | https://conductscience.org/library/papers/41893011 | PubMed |
| 41858526 | Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review. | Breast Cancer (Dove Med Press) | 2026 | https://conductscience.org/library/papers/41858526 | PubMed |
| 41714320 | mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR+/HER2- breast cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41714320 | PubMed |
| 41677624 | Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. | Cells | 2026 | https://conductscience.org/library/papers/41677624 | PubMed |
| 41646442 | Rectal metastasis in a patient with long-term breast cancer: a rare case report with literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/41646442 | PubMed |
| 41594633 | Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer. | Biomolecules | 2026 | https://conductscience.org/library/papers/41594633 | PubMed |
| 41351070 | Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41351070 | PubMed |
| 41236673 | Decoding breast cancer: insights into molecular pathways & therapeutic approaches. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41236673 | PubMed |
| 41144934 | Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing. | J Pathol | 2026 | https://conductscience.org/library/papers/41144934 | PubMed |
| 40949156 | Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40949156 | PubMed |
| 40947659 | Effect of Neoadjuvant Hormonal Therapy on Breast Conservation in Invasive Ductal Versus Lobular Carcinoma of the Breast: A Comparative Analysis. | J Surg Oncol | 2025 | https://conductscience.org/library/papers/40947659 | PubMed |
| 40830892 | Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer. | Breast Cancer Res | 2025 | https://conductscience.org/library/papers/40830892 | PubMed |
| 40740245 | Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis. | J Cancer | 2025 | https://conductscience.org/library/papers/40740245 | PubMed |
| 40736275 | PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion. | Oncotarget | 2025 | https://conductscience.org/library/papers/40736275 | PubMed |
Genes46
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37035239
GET https://conductscience.org/api/papers/v1/37035239/references?page=2